Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). Issue 1 (17th January 2018)

• Record Type: Journal Article
• Authors: Meng, En; Hsu, Yu‐Chao; Chuang, Yao‐Chi
• Is Part Of: LUTS. Volume 10:Issue 1(2018)
• Page Start: 3
• Page End: 11
• Publication Date: 2018-01-17
• Subjects: bladder pain syndrome -- interstitial cystitis -- intravesical therapy; Urology -- Periodicals; Urologic Diseases -- Periodicals; Urinary Tract Physiological Phenomena -- Periodicals; 616.62
• DOI: 10.1111/luts.12214
• Languages: English
• ISSNs: 1757-5664

Abstract

Abstract : Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic symptom complex that may cause bothersome storage symptoms and pain or discomfort of the bladder, adversely affecting a patient's quality of life. The etiology of IC/BPS remains unclear, and its cause may be multifactorial. Diagnosis of IC/BPS is based on clinical features, and the possibility of other conditions must be ruled out first. Although no definitive treatment is currently available for IC/BPS, various intravesical therapies are used for IC/BPS, including heparin, hyaluronic acid, chondroitin sulfate, pentosan polysulfate, dimethylsulfoxide, liposomes, and botulinum onabotulinumtoxinA (BoNT‐A). This review summarizes the intravesical therapy for IC/BPS and discusses recent advances in the instillation of liposomal‐mediated BoNT‐A and other newly developed intravesical therapies.